Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss	$ (662)	$ (610)
Adjustments to reconcile net loss to net cash used in operating activities
Gain on sale of in-process research and development	(139)	(445)
Accretion on short-term investments	(26)
Stock-based compensation expense	64	37
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(85)	(210)
Accounts payable, accrued expenses and other	(178)	(121)
Other assets	2	56
Net cash used in operating activities	(1,024)	(1,293)
Cash flows from investing activities
Net proceeds from sale of in process research and development	139	445
Purchases of short-term investments	(8,811)
Net cash (used in) provided by investing activities	(8,672)	445
Cash flows from financing activities
Proceeds from exercise of stock options	388
Net cash provided by financing activities	388
Net decrease in cash and cash equivalents	(9,308)	(848)
Cash and cash equivalents, beginning of period	19,439	14,203
Cash and cash equivalents, end of period	$ 10,131	$ 13,355